Novartis loses legal battle to block US Entresto generic until 2026
Washington: In a significant legal setback for Novartis, a Delaware federal judge has said that Swiss pharmaceutical giant cannot stop Indian drugmaker MSN Pharmaceuticals from launching a generic version of Entresto, its blockbuster heart-failure medication, before a key patent expires in late 2026.
U.S. District Judge Richard Andrews issued the ruling on Friday, denying Novartis’ request for an injunction that would have prevented MSN from launching its generic drug until after the patent’s expiration in November 2026. The judge rejected Novartis’ claim that MSN’s version would infringe on its patents, Reuters reported.
Novartis told the court in a separate filing on Friday that India-based MSN may receive U.S. Food and Drug Administration approval for the generic as soon as July 16 and launch it soon after. The generic would cut into the U.S. market for Swiss-based Novartis' best-selling drug, which earned more than $7.8 billion in global revenue last year.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.